[Anti VEGF Therapy Under Real-Life Conditions: Adherance Determines Long Term Outcome in Neovascular AMD].
Data from real-life studies on neovascular AMD (nvAMD) generally fall significantly behind respective data from interventional prospective trials. This can be attributed at least partially to differences in patient cohorts concerning both stages of AMD (including consecutive scarring or atrophy), as well as adherence to therapy. We have been interested in the question which of the two factors most affects outcome in a real-life setting. Retrospective study of 1500 cases of nvAMD over a time period of up to 5 years. Inclusion of all cases treated for nvAMD which received at least 3 intravitreal injections, no exclusion of cases. Treatment was according to pro re nata (PRN) scheme. In total, results for gain in visual acuity (letter score + 1,4 and - 0,8 for year 1 and 2, respectively), and number of injections (5,2 and 3,3) are well comparable to data from other German real-life studies. The variance within the dataset, however, is relatively large. Definition of one subgroup characterized by significantly better baseline visual acuity and significantly higher number of injections demonstrates expectedly significantly better outcome. This better performance, however, is outranged by a subgroup defined only by its significantly higher adherence to therapy. In fact, only approx. 30 % of all cases fall into this category and followed the desired PRN intervals reasonably well. This group shows gain in visual acuity of + 3,3 and + 1,6 with number of injections of 7,0 and 5,8 while not being selected according to stages of AMD at baseline. In this setting adherence to treatment more than the stage of nvAMD at baseline determined long term outcome of anti-VEGF treatment. This is encouraging for every days work where unfortunately late stages of AMD are not seen rarely. This finding emphases the importance of patient counseling and information to improve adherence to treatment.